Skip to main content

United Therapeutics Corporation (UTHR) Stock Analysis

Range Bound setup

SellVALUE-TRAP 1/5Moderate Confidence

Healthcare · Drug Manufacturers - Specialty & Generic

Sell if holding. At $570.10, A.R:R 0.3:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Tyvaso DPI and Nebulized Tyvaso (59.0%); Concentration risk — Supplier: MannKind.

United Therapeutics (a public benefit corporation) markets five FDA-approved therapies for pulmonary arterial hypertension and Unituxin for neuroblastoma, with Tyvaso DPI and Nebulized Tyvaso combined representing 59% of 2025 revenues. Revenue comes primarily from sales to... Read more

$570.10+1.5% A.UpsideScore 4.8/10#23 of 29 Drug Manufacturers - Specialty & Generic
QualityF-score6 / 9FCF yield2.35%
Stop $543.36Target $577.32(analyst − 13%)A.R:R 0.3:1
Analyst target$663.58+16.4%12 analysts
$577.32our TP
$570.10price
$663.58mean
$516
$750

Sell if holding. At $570.10, A.R:R 0.3:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Tyvaso DPI and Nebulized Tyvaso (59.0%); Concentration risk — Supplier: MannKind. Chart setup: RSI 51 mid-range, Bollinger mid-band. Score 4.8/10, moderate confidence.

Passes 5/7 gates (clean insider activity, no SEC red flags, earnings proximity 73d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.

Val5.2Qual7.3Grw1.1Mom2.9Sent7.5Ins3.1Peer4.5Tech7.9Risk6.74.8OVERALL

Recent Developments — United Therapeutics Corporation

Latest news

Generated 2026-05-20T20:21:22Z.

Thesis

Rewards
V7 quality resilience bonus: +0.2 (Q=7.3 in RISK_OFF)
Sector modifier (Healthcare): +0.5
High-quality business
Risks
Concentration risk — Product: Tyvaso DPI and Nebulized Tyvaso (59.0%)
Concentration risk — Supplier: MannKind
Analyst target reached - limited upside remaining

Key Metrics

P/E (TTM)21.0
P/E (Fwd)17.4
Mkt Cap$24.1B
EV/EBITDA14.2
Profit Mgn40.6%
ROE20.3%
Rev Growth-1.6%
Beta0.59
DividendNone
Rating analysts22

Quality Signals

Piotroski F6/9MoatNarrow

Concentration Risks(10-K Item 1A)

  • HIGHProductTyvaso DPI and Nebulized Tyvaso59%
    10-K Item 1: 'combined Tyvaso DPI and Nebulized Tyvaso net product sales, representing 59 percent...of our total revenues for the years ended December 31, 2025'
  • HIGHSupplierMannKind
    10-K Item 1A: 'We rely entirely on MannKind to manufacture Tyvaso DPI finished drug product and inhalers for us, with no plans to develop an alternate or backup supply arrangement'
  • HIGHCustomerAccredo and CVS Specialty
    10-K Item 1A: 'we derive substantially all our treprostinil-based revenues from sales to two distributors, Accredo and CVS Specialty'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers

Revenue shrinking — -1.6% YoY. Growth thesis broken unless recovery story develops.static

Earnings Growth
0.0
Revenue Growth
2.1
Declining revenue: -2%

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd
0.0
Obv
1.0
Volume
2.1
Rsi
5.5
Ma Position
6.0
Volume distribution (falling OBV)Above 200-day MA
GatesMomentum 2.9<4.5A.R:R 0.3 < 1.5@spotInsider activity: OKNo SEC red flagsEARNINGS PROXIMITY 73d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRange BoundSuitability: Moderate
RSI
51 · Neutral
↓ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $560.16Resistance $609.35

Price Targets

$543
$577
A.Upside+1.3%
A.R:R0.3:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeRisk-Off

Risk Alerts

! Target reached (1.5% upside)
! Momentum score 2.9/10 — below 4.5 minimum
! Reward/Risk 0.3:1 at current price — below 1.5:1 minimum

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-07-29 (73d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is UTHR stock a buy right now?

Sell if holding. At $570.10, A.R:R 0.3:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Tyvaso DPI and Nebulized Tyvaso (59.0%); Concentration risk — Supplier: MannKind. Chart setup: RSI 51 mid-range, Bollinger mid-band. Prior stop was $543.36. Score 4.8/10, moderate confidence.

What is the UTHR stock price target?

Take-profit target: $577.32 (+1.5% upside). Prior stop was $543.36. Stop-loss: $543.36.

What are the risks of investing in UTHR?

Concentration risk — Product: Tyvaso DPI and Nebulized Tyvaso (59.0%); Concentration risk — Supplier: MannKind; Analyst target reached - limited upside remaining.

Is UTHR overvalued or undervalued?

United Therapeutics Corporation trades at a P/E of 21.0 (forward 17.4). TrendMatrix value score: 5.2/10. Verdict: Sell.

What do analysts say about UTHR?

22 analysts cover UTHR with a consensus score of 4.1/5. Average price target: $664.

What does United Therapeutics Corporation do?United Therapeutics (a public benefit corporation) markets five FDA-approved therapies for pulmonary arterial...

United Therapeutics (a public benefit corporation) markets five FDA-approved therapies for pulmonary arterial hypertension and Unituxin for neuroblastoma, with Tyvaso DPI and Nebulized Tyvaso combined representing 59% of 2025 revenues. Revenue comes primarily from sales to specialty distributors Accredo and CVS Specialty; MannKind is the sole Tyvaso DPI manufacturer with no backup arrangement.

Related stocks: NBIX (Neurocrine Biosciences, Inc.) · INDV (Indivior Pharmaceuticals, Inc.) · LNTH (Lantheus Holdings, Inc.) · ALKS (Alkermes plc) · KNSA (Kiniksa Pharmaceuticals Interna)